Glucose-dependent Insulinotropic Polypeptide (human) (trifluoroacetate salt)

Name: Glucose-dependent Insulinotropic Polypeptide (human) (trifluoroacetate salt)
Brand: GlpBio
SKU: GC92134
Availability: InStock

Catalog No.: GC92134Purity:>95.00%Synonyms: Gastric Inhibitory Peptide; GIP

COASDSData Sheet

Glucose-dependent Insulinotropic Polypeptide (human) (trifluoroacetate salt) es una hormona incretina peptídica endógena de 42 aminoácidos que induce la secreción de insulina en respuesta a la glucosa.

Los productos son exclusivamente para uso en investigación. No aptos para uso humano. No vendemos a pacientes.

1 mgIn Stock

$419.00

Pack Size	Price	Availability	Quantity	Action
1 mg	$419.00	In Stock	1

Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

Citas (Citations)

Actualmente no hay citas disponibles para este producto. A continuación se muestran publicaciones seleccionadas que citan productos GlpBio.

Nature
641, 529–536 (2025)
Nature
628, 630–638 (2024)
Nature
632, 686–694 (2024)
Nature
618, 1017–1023 (2023)
Nature
610, 366–372 (2022)
Cell
187(9):2288-2304 (2024)
Cell
183(7):1867-1883 (2020)
Science
388(6745) (2025)
Science
387(6739) (2025)
Science
387(6734) (2025)
Cell Research
35, 97–116 (2025)
Cell Research
34, 683–706 (2024)
Cell Research
33, 273–287 (2023)
Cell Research
33, 546–561 (2023)
Cell Research
33, 904–922 (2023)
Cell Research
31, 1291–1307 (2021)

Descripción (Description)

Glucose-dependent Insulinotropic Polypeptide (GIP) (human) is an endogenous 42-amino acid peptide incretin hormone that induces insulin secretion in response to glucose.¹ It belongs to the secretin/glucagon superfamily of peptides, which includes secretin, glucagon, glucagon-like peptide-1 (GLP-1, GLP-2), and pituitary adenylate cyclase-activating polypeptide (PACAP).² GIP is a GIP receptor agonist that binds to rat recombinant GIP receptors expressed in CHO-K1 cells (IC₅₀ = 3.2 nM) and increases cAMP accumulation (EC₅₀ = 377 pM).³ It stimulates insulin secretion from BRIN-BD11 rat pancreatic β-cells when used at a concentration of 10 nM.⁴ GIP (1 pmol/min per 100 g) decreases blood glucose level and increases plasma insulin level in rats following glucose challenge.³ It also decreases plasma glucose level and increases insulin level in ob/ob mice following glucose challenge when administered at a dose of 25 nmol/kg.⁵

References:
[1]. Baggio, L.L., and Drucker, D.J.Biology of incretins: GLP-1 and GIPGastroenterology132(6)2131-2157(2007).
[2]. Vaudry, D., Falluel-Morel, A., Bourgault, S., et al.Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discoveryPharmacol. Rev.61(3)283-357(2009).
[3]. Hinke, S.A., Manhart, S., Pamir, N., et al.Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP)Biochim. Biophys. Acta1547(1)143-155(2001).
[4]. Kerr, B.D., Flatt, A.J., Flatt, P.R., et al.Characterization and biological actions of N-terminal truncated forms of glucose-dependent insulinotropic polypeptideBiochem. Biophys. Res. Commun.404(3)870-876(2011).
[5]. O'Harte, F.P., Hunter, K., Gault, V.A., et al.Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob miceAm. J. Physiol. Endocrinol. Metab.292(6)E1674-E1682(2007).

Documentos del producto (Product Documents)

Batch:Purity:>95.00%Appearance:A solid

COA SDS Data Sheet

Propiedades químicas (Chemical Properties)

Sinónimos

Gastric Inhibitory Peptide; GIP

Nombre químico

L-tyrosyl-L-alanyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-isoleucyl-L-seryl-L-α-aspartyl-L-tyrosyl-L-seryl-L-isoleucyl-L-alanyl-L-methionyl-L-α-aspartyl-L-lysyl-L-isoleucyl-L-histidyl-L-glutaminyl-L-glutaminyl-L-α-aspartyl-L-phenylalanyl-L-valyl-L-asparaginyl-L-tryptophyl-L-leucyl-L-leucyl-L-alanyl-L-glutaminyl-L-lysylglycyl-L-lysyl-L-lysyl-L-asparaginyl-L-α-aspartyl-L-tryptophyl-L-lysyl-L-histidyl-L-asparaginyl-L-isoleucyl-L-threonyl-L-glutamine, trifluoroacetate salt

SMILES

[H]N[C@H](C(N[C@H](C(N[C@@H](CCC(O)=O)C(NCC(N[C@]([C@@H](C)O)([H])C(N[C@H](C(N[C@]([C@H](CC)C)([H])C(N[C@@H](CO)C(N[C@H](C(N[C@H](C(N[C@@H](CO)C(N[C@]([C@H](CC)C)([H])C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CCCCN)C(N[C@]([C@H](CC)C)([H])C(N[C@H](C(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(N)=O)C(N[C@H](C(N[C@H](C(N[C@@H](C(C)C)C(N[C@@H](CC(N)=O)C(N[C@H](C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@H](C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(NCC(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CC(N)=O)C(N[C@H](C(N[C@H](C(N[C@@H](CCCCN)C(N[C@H](C(N[C@@H](CC(N)=O)C(N[C@]([C@H](CC)C)([H])C(N[C@]([C@@H](C)O)([H])C(N[C@@H](CCC(N)=O)C(O)=O)=O)=O)=O)=O)CC1=CN=CN1)=O)=O)CC2=CNC3=C2C=CC=C3)=O)CC(O)=O)=O)=O)=O)=O)=O)=O)=O)C)=O)=O)=O)CC4=CNC5=C4C=CC=C5)=O)=O)=O)CC6=CC=CC=C6)=O)CC(O)=O)=O)=O)=O)CC7=CN=CN7)=O)=O)=O)CC(O)=O)=O)CCSC)=O)C)=O)=O)=O)CC8=CC=C(O)C=C8)=O)CC(O)=O)=O)=O)=O)CC9=CC=CC=C9)=O)=O)=O)=O)C)=O)CC%10=CC=C(O)C=C%10.FC(F)(C(O)=O)F

Fórmula molecular

C₂₂₆H₃₃₈N₆₀O₆₆S ? XCF₃COOH

Peso molecular

4983.5

Solubilidad

Water: 1 mg/ml

Almacenamiento

-20°C

Consejos generales

Seleccione un disolvente adecuado según los datos de solubilidad del producto. Una vez preparada, divida la solución madre en alícuotas para evitar ciclos repetidos de congelación y descongelación.
Utilice las soluciones madre en un plazo de 6 meses si se conservan a -80°C, o de 1 mes si se conservan a -20°C.
Para mejorar la solubilidad, caliente el tubo a 37°C y soníquelo durante un periodo adecuado.

Condiciones de envío

Las muestras de evaluación se envían con acumuladores de frío. Los demás tamaños se envían a temperatura ambiente o, previa solicitud, con acumuladores de frío.

Calculadoras (Calculators)Molaridad / Dilución / Peso molecular / Conversión de unidades / Formulación in vivo / Solubilidad

Masa

Volumen

Concentración

Peso molecular

g/mol

Reviews

Review for Glucose-dependent Insulinotropic Polypeptide (human) (trifluoroacetate salt)

Rating: 5

5 Star100%
4 Star0%
3 Star0%
2 Star0%
1 Star0%